
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11203906/publications.pdf Version: 2024-02-01



FARIO ANCELL

#	Article	IF	CITATIONS
1	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine, 2020, 76, 14-20.	1.0	980
2	Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension, 2004, 43, 963-969.	1.3	476
3	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet, The, 2009, 374, 525-533.	6.3	391
4	Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension, 2005, 46, 386-392.	1.3	317
5	Atrial Fibrillation in Hypertension. Hypertension, 2003, 41, 218-223.	1.3	289
6	Short- and Long-Term Incidence of Stroke in White-Coat Hypertension. Hypertension, 2005, 45, 203-208.	1.3	271
7	Day-Night Dip and Early-Morning Surge in Blood Pressure in Hypertension. Hypertension, 2012, 60, 34-42.	1.3	264
8	Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension, 2003, 16, 895-899.	1.0	263
9	Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension. American Journal of Hypertension, 2007, 20, 154-161.	1.0	156
10	Hypertension and Atrial Fibrillation. Circulation Research, 2018, 122, 352-368.	2.0	151
11	Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. Journal of the American College of Cardiology, 2002, 39, 878-885.	1.2	133
12	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. Journal of Hypertension, 2008, 26, 1282-1289.	0.3	121
13	Ambulatory Blood Pressure and Cardiovascular Outcome in Relation to Perceived Sleep Deprivation. Hypertension, 2007, 49, 777-783.	1.3	116
14	Electrocardiographic features of patients with COVID-19 pneumonia. European Journal of Internal Medicine, 2020, 78, 101-106.	1.0	111
15	Association Between Periodontal Disease and Left Ventricle Mass in Essential Hypertension. Hypertension, 2003, 41, 488-492.	1.3	104
16	SARS-CoV-2 vaccines: Lights and shadows. European Journal of Internal Medicine, 2021, 88, 1-8.	1.0	90
17	Masked Hypertension: Evaluation, Prognosis, and Treatment. American Journal of Hypertension, 2010, 23, 941-948.	1.0	88
18	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vascular Health and Risk Management, 2008, Volume 4, 971-981.	1.0	76

FABIO ANGELI

#	Article	IF	CITATIONS
19	More Versus Less Intensive Blood Pressure–Lowering Strategy. Hypertension, 2016, 68, 642-653.	1.3	75
20	Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease. Hypertension, 2015, 65, 108-114.	1.3	70
21	Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events?. Current Opinion in Cardiology, 2007, 22, 329-334.	0.8	66
22	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. European Heart Journal, 2008, 30, 679-688.	1.0	66
23	Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. American Journal of Hypertension, 2004, 17, 817-822.	1.0	65
24	COVID-19. Hypertension, 2020, 76, 294-299.	1.3	64
25	Regression of Left Ventricular Hypertrophy and Prevention of Stroke in Hypertensive Subjects. American Journal of Hypertension, 2006, 19, 493-499.	1.0	60
26	Improved cardiovascular risk stratification by a simple ECG index in hypertension. American Journal of Hypertension, 2003, 16, 646-652.	1.0	59
27	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension, 2009, 54, 188-195.	1.3	56
28	The Evolution and Refinement of Traditional Risk Factors for Cardiovascular Disease. Cardiology in Review, 2012, 20, 118-129.	0.6	56
29	Ambulatory Blood Pressure for Cardiovascular Risk Stratification. Circulation, 2007, 115, 2091-2093.	1.6	53
30	The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations. European Journal of Internal Medicine, 2020, 82, 1-6.	1.0	53
31	The clinical significance of white-coat and masked hypertension. Blood Pressure Monitoring, 2007, 12, 387-389.	0.4	52
32	White-coat hypertension in adults. Blood Pressure Monitoring, 2005, 10, 301-305.	0.4	50
33	Hypertension, inflammation and atrial fibrillation. Journal of Hypertension, 2014, 32, 480-483.	0.3	42
34	Clinical Usefulness of Ambulatory Blood Pressure Monitoring. Journal of the American Society of Nephrology: JASN, 2004, 15, 30S-33.	3.0	41
35	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. European Journal of Internal Medicine, 2021, 93, 28-34.	1.0	40
36	Prognostic Value of Serial Electrocardiographic Voltage and Repolarization Changes in Essential Hypertension: The HEART Survey Study. American Journal of Hypertension, 2007, 20, 997-1004.	1.0	39

#	Article	IF	CITATIONS
37	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vascular Health and Risk Management, 2009, 5, 411.	1.0	39
38	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin–angiotensin system blockers. Therapeutic Advances in Cardiovascular Disease, 2012, 6, 81-91.	1.0	39
39	Diuretic Treatment of Hypertension. Diabetes Care, 2011, 34, S313-S319.	4.3	38
40	Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. European Journal of Internal Medicine, 2021, 90, 111-113.	1.0	38
41	Left Ventricular Hypertrophy and Obesity: Only a Matter of Fat?. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 29-41.	1.0	35
42	Estimate of white-coat effect and arterial stiffness. Journal of Hypertension, 2007, 25, 827-831.	0.3	33
43	COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the "Spike effect". European Journal of Internal Medicine, 2022, 103, 23-28.	1.0	32
44	Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease. Hypertension, 2014, 63, 475-482.	1.3	31
45	New-onset diabetes in treated hypertensive patients. Current Hypertension Reports, 2005, 7, 174-179.	1.5	28
46	Usefulness of QRS Voltage Correction by Body Mass Index to Improve Electrocardiographic Detection of Left Ventricular Hypertrophy in Patients With Systemic Hypertension. American Journal of Cardiology, 2014, 114, 427-432.	0.7	28
47	How Can We Use the Results of Ambulatory Blood Pressure Monitoring in Clinical Practice?. Hypertension, 2005, 46, 25-26.	1.3	25
48	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. Journal of Hypertension, 2020, 38, 1190-1191.	0.3	25
49	Aliskiren versus ramipril in hypertension. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 193-200.	1.0	23
50	The prognostic legacy of left ventricular hypertrophy. Journal of Hypertension, 2015, 33, 2322-2330.	0.3	22
51	Is the definition of daytime and nighttime blood pressure prognostically relevant?. Blood Pressure Monitoring, 2008, 13, 153-155.	0.4	21
52	Hypertension and the J-curve phenomenon: implications for tight blood pressure control. Hypertension Research, 2013, 36, 109-111.	1.5	21
53	New-Onset Diabetes, Antihypertensive Treatment, and Outcome. Hypertension, 2007, 50, 459-460.	1.3	20
54	Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 379-385.	1.5	20

#	Article	IF	CITATIONS
55	European and US guidelines for arterial hypertension: similarities and differences. European Journal of Internal Medicine, 2019, 63, 3-8.	1.0	20
56	Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. Expert Review of Cardiovascular Therapy, 2014, 12, 623-634.	0.6	19
57	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. Expert Review of Clinical Pharmacology, 2018, 11, 1073-1084.	1.3	19
58	Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19. European Journal of Internal Medicine, 2021, 89, 81-86.	1.0	18
59	The 2014 hypertension guidelines: implications for patients and practitioners in Asia. Heart Asia, 2015, 7, 21-25.	1.1	17
60	Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opinion on Drug Safety, 2012, 11, 659-670.	1.0	16
61	Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry. Journal of Cardiovascular Development and Disease, 2022, 9, 15.	0.8	16
62	Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 150.	0.8	16
63	Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. Journal of the American Society of Hypertension, 2008, 2, 88-96.	2.3	15
64	Treatment strategies for osteoarthritis patients with pain and hypertension. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 229-240.	1.2	15
65	Fixed-Dose Combination Therapy in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 51-54.	1.0	15
66	Ageing, ACE2 deficiency and bad outcome in COVID-19. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1607-1609.	1.4	15
67	Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. Cardiology and Therapy, 2021, 10, 397-406.	1.1	15
68	SARS-CoV-2 infection and ACE2 inhibition. Journal of Hypertension, 2021, 39, 1555-1558.	0.3	15
69	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	1.1	15
70	Optimal Use of the Non-Inferiority Trial Design. Pharmaceutical Medicine, 2020, 34, 159-165.	1.0	14
71	Interpretation of ambulatory blood pressure profile. Journal of Hypertension, 2015, 33, 454-457.	0.3	13
72	Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	13

#	Article	IF	CITATIONS
73	Blood pressure increase during hospitalization for COVID-19. European Journal of Internal Medicine, 2022, 104, 110-112.	1.0	13
74	The Optimal Blood Pressure Target for Patients with Coronary Artery Disease. Current Cardiology Reports, 2010, 12, 302-306.	1.3	12
75	Neutrophil Count for the Identification of Postmenopausal Hypertensive Women at Increased Cardiovascular Risk. Obstetrics and Gynecology, 2010, 115, 695-703.	1.2	12
76	Above Which Blood Pressure Level Does the Risk of Atrial Fibrillation Increase?. Hypertension, 2012, 59, 184-185.	1.3	12
77	Advances in the Treatment Strategies in Hypertension: Present and Future. Journal of Cardiovascular Development and Disease, 2022, 9, 72.	0.8	12
78	Does Brachial Pulse Pressure Predict Coronary Events?. , 2006, 44, 150-159.		11
79	Severity of COVID-19: The importance of being hypertensive. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	11
80	Ambulatory blood pressure monitoring and prognosis in the management of essential hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 79-89.	0.6	10
81	"The Lower the BP the Better―Paradigm in the Elderly. Hypertension, 2010, 56, 182-184.	1.3	10
82	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 115-128.	1.5	10
83	Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. Acute Cardiac Care, 2012, 14, 34-39.	0.2	10
84	Fixed-Dose Combination Therapy in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 51-54.	1.0	10
85	Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations. European Journal of Internal Medicine, 2022, 95, 7-12.	1.0	10
86	Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. Expert Opinion on Pharmacotherapy, 2022, 23, 235-242.	0.9	10
87	Reversal of Left Ventricular Hypertrophy. American Journal of Cardiovascular Drugs, 2004, 4, 369-378.	1.0	9
88	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	0.8	9
89	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis. European Journal of Internal Medicine, 2022, 101, 49-55.	1.0	9
90	Angiotensin receptor blockers in hypertension. New insights from Japan. Hypertension Research, 2010, 33, 394-397.	1.5	8

#	Article	IF	CITATIONS
91	The natural history of white-coat hypertension in the long term. Blood Pressure Monitoring, 2005, 10, 65-66.	0.4	7
92	Is the Development of Diabetes With Antihypertensive Therapy a Problem?—Pro. Journal of Clinical Hypertension, 2006, 8, 120-126.	1.0	7
93	Left Ventricular Hypertrophy and Coronary Artery Calcifications: A Dangerous Duet?. American Journal of Hypertension, 2018, 31, 287-289.	1.0	7
94	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. European Journal of Internal Medicine, 2020, 71, 15-17.	1.0	7
95	Blood pressure variability and risk of stroke in chronic kidney disease. Journal of Hypertension, 2020, 38, 599-602.	0.3	7
96	Hypertension and Arrhythmias: A Clinical Overview of the Pathophysiology-Driven Management of Cardiac Arrhythmias in Hypertensive Patients. Journal of Cardiovascular Development and Disease, 2022, 9, 110.	0.8	7
97	Twenty–four hour ambulatory blood pressure monitoring to all? Comments to the US Preventive Services Task Force document. Journal of the American Society of Hypertension, 2015, 9, 911-915.	2.3	6
98	How Low Should We Go With Blood Pressure?. Circulation Research, 2017, 120, 27-29.	2.0	6
99	Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. Journal of Human Hypertension, 2018, 32, 625-632.	1.0	6
100	Treatment strategies for isolated systolic hypertension in elderly patients. Expert Opinion on Pharmacotherapy, 2020, 21, 1713-1723.	0.9	6
101	Device-Pocket Hematoma after Cardiac Implantable Electronic Devices. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008372.	2.1	6
102	Does Malaria Cause Hypertension?. Circulation Research, 2016, 119, 7-9.	2.0	5
103	The Link Between Inflammation and Hypertension: Unmasking Mediators. American Journal of Hypertension, 2021, 34, 683-685.	1.0	5
104	Combined Use of Electrocardiography and Ultrasound to Detect Cardiac and Pulmonary Involvement after Recovery from COVID-19 Pneumonia: A Case Series. Journal of Cardiovascular Development and Disease, 2021, 8, 133.	0.8	5
105	Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study. Current Therapeutic Research, 2008, 69, 207-220.	0.5	4
106	PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 533-541.	1.5	4
107	Pentraxin-3 and the pathogenesis of preeclampsia. Hypertension Research, 2020, 43, 979-981.	1.5	4
108	Long-Term Survival in Patients with Post-Operative Atrial Fibrillation after Cardiac Surgery: Analysis from a Prospective Cohort Study. Journal of Cardiovascular Development and Disease, 2021, 8, 169.	0.8	4

#	Article	IF	CITATIONS
109	Optimizing the definition of dippers and nondippers: is a 70–86% full glass empty?. Journal of Hypertension, 2008, 26, 630-632.	0.3	3
110	The emerging role of high-density lipoprotein cholesterol in hypertension trials. Journal of Hypertension, 2009, 27, 458-460.	0.3	3
111	Echocardiographic left ventricular hypertrophy. Journal of Hypertension, 2012, 30, 2279-2284.	0.3	3
112	Intensive Blood Pressure Lowering and Regression of Left Ventricular Hypertrophy. Circulation, 2017, 136, 451-453.	1.6	3
113	Electrocardiography for diagnosis of left ventricular hypertrophy in hypertensive patients with atrial fibrillation. International Journal of Cardiology: Hypertension, 2019, 1, 100004.	2.2	3
114	Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. American Journal of Cardiovascular Drugs, 2020, 20, 229-238.	1.0	3
115	An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?. Expert Opinion on Pharmacotherapy, 2021, 22, 2033-2051.	0.9	3
116	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. Expert Review of Cardiovascular Therapy, 2008, 6, 1171-1174.	0.6	2
117	Clinical Significance of the Blood Pressure Changes from Day to Night. Current Hypertension Reviews, 2011, 7, 13-19.	0.5	2
118	Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. Hypertension Research, 2012, 35, 17-19.	1.5	2
119	Response to Morning Surge, Dipping, and Sleep-Time Blood Pressure as Prognostic Markers of Cardiovascular Risk. Hypertension, 2013, 61, .	1.3	2
120	Masked and White-Coat Hypertension. Journal of the American College of Cardiology, 2015, 66, 2170-2172.	1.2	2
121	Prognostic Value of Ambulatory Blood Pressure Monitoring. , 2016, , 165-191.		2
122	Management of hypertension in the very old: an intensive reduction of blood pressure should be achieved in most patients. Journal of Human Hypertension, 2020, 34, 551-556.	1.0	2
123	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation. European Heart Journal, 2021, 42, 2019-2019.	1.0	2
124	Masked Nocturnal Hypertension: A Complex Phenomenon to Detect in Clinical Practice. American Journal of Hypertension, 2021, 34, 578-580.	1.0	2
125	Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes. Hypertension, 2022, 79, 1028-1036.	1.3	2
126	The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 1-3.	1.0	1

#	Article	IF	CITATIONS
127	Emerging therapies in the management of hypertensive patients with osteoarthritis. Clinical Investigation, 2011, 1, 125-136.	0.0	1
128	Cardiac Benefits of an Intensive Blood Pressure Control in Diabetes Mellitus. Hypertension, 2015, 66, 1104-1105.	1.3	1
129	Alcohol intake and atrial fibrillation: A new topic in gender medicine. European Journal of Internal Medicine, 2020, 76, 23-25.	1.0	1
130	Use of Antibiotics and Mortality in Women. Circulation Research, 2020, 126, 374-376.	2.0	1
131	The Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) Study. Panminerva Medica, 2021, , .	0.2	1
132	African Ancestry and Uncontrolled Hypertension: Current Knowledge and Future Perspectives. American Journal of Hypertension, 2021, 34, 1255-1258.	1.0	1
133	Risk of stroke in white-coat hypertension: a multinational registry. American Journal of Hypertension, 2003, 16, A65.	1.0	0
134	Antihypertensive Drugs and Coronary Artery Disease. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 119???124.	1.0	0
135	Response to Why Is Nondipping in Ambulatory Blood Pressure Monitoring Not Prognostic in Poor Sleepers?. Hypertension, 2007, 50, .	1.3	0
136	Response to Body Position and Quality of Sleep Interfere With Day-Night Blood Pressure Dip. Hypertension, 2012, 60, .	1.3	0
137	Response to Do Extreme Dippers Have a Lower Cardiovascular Risk Than Dippers?. Hypertension, 2012, 60, .	1.3	0
138	Response to Role of Yin and Yang in Diurnal Blood Pressure Variation for Cardiovascular Disease. Hypertension, 2012, 60, .	1.3	0
139	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. Italian Journal of Medicine, 2012, 6, 302-306.	0.2	0
140	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. Italian Journal of Medicine, 0, , .	0.2	0
141	Home blood pressure and treatment decisions. Journal of Hypertension, 2016, 34, 1494-1496.	0.3	0
142	Hypertensive Heart Disease. Updates in Hypertension and Cardiovascular Protection, 2018, , 189-212.	0.1	0
143	Soluble CD40 ligand and outcome in patients with coronary artery disease undergoing percutaneous coronary intervention. Clinical Chemistry and Laboratory Medicine, 2021, 60, 118-126.	1.4	0
144	Prognostic Value of Ambulatory Blood Pressure Monitoring. , 2007, , 225-252.		0

#	Article	IF	CITATIONS
145	512â€fLong-term survival in patients with post-operative atrial fibrillation after cardiac surgery: analysis from a prospective-cohort study. European Heart Journal Supplements, 2021, 23, .	0.0	0